C-Terminally PEGylated hGH-derivatives.

Area of Science:

• Biochemistry
• Chemical Biology
• Drug Development

Background:

• Human growth hormone (hGH) is a vital protein hormone with therapeutic applications.
• PEGylation is a common strategy to improve the pharmacokinetic properties of protein therapeutics.
• Developing novel PEGylated hGH derivatives requires efficient and specific conjugation methods.

Purpose of the Study:

• To develop a robust two-step strategy for C-terminally PEGylated hGH derivatives.
• To investigate the impact of polyethylene glycol (PEG) size and shape on the biological activity of modified hGH.
• To explore different ligation chemistries for PEG attachment to hGH.

Main Methods:

• Utilized a CPY-catalyzed transpeptidation reaction to introduce reaction handles onto hGH.
• Employed oxime ligation and copper(I)-catalyzed [2+3]-cycloaddition reactions for PEG moiety attachment.
• Synthesized C-terminally PEGylated hGH derivatives with varying PEG sizes and shapes.

Main Results:

• Successfully prepared C-terminally PEGylated hGH derivatives using the developed two-step strategy.
• Demonstrated that both the size and shape of the attached PEG group influence the biological potency of the hGH derivatives.
• Oxime ligation and copper(I)-catalyzed [2+3]-cycloaddition proved effective for PEGylation.

Conclusions:

• The developed two-step PEGylation strategy is effective for creating C-terminally modified hGH.
• The biological activity of PEGylated hGH is sensitive to the physicochemical properties of the PEG conjugate.
• This work provides insights into the rational design of PEGylated protein therapeutics.